Pharmacogenetics and the serotonin transporter in late-life depression

Bibliography

• Juurlink DN, Mamdani MM, Kopp A, Redelmeier DA. The risk of suicide with selective serotonin reuptake inhibitors in the elderly. Am J Psychiatry 2006;163:813-21
   PubMed Web of Science ®Google Scholar
• Klap R, Unroe KT, Unutzer J. Caring for mental illness in the United States: a focus on older adults. Am J Geriatr Psychiatry 2003;11:517-24
   PubMed Web of Science ®Google Scholar
• Lyness JM, Caine ED, King DA, et al. Psychiatric disorders in older primary care patients. J Gen Intern Med 1999;14:249-54
   PubMed Web of Science ®Google Scholar
• Hybels CF, Blazer DG. Epidemiology of late-life mental disorders. Clin Geriatr Med 2003;19:663-96
   PubMed Web of Science ®Google Scholar
• Horwath E, Johnson J, Klerman GL, Weissman MM. Depressive symptoms as relative and attributable risk factors for first-onset major depression. Arch Gen Psychiatry 1992;49:817-23
   PubMed Web of Science ®Google Scholar
• Unutzer J. Late-life depression. NEJM 2006;357:2269-76
   Web of Science ®Google Scholar
• Driscoll HC, Basinski J, Mulsant BH, et al. Late-onset major depression: clinical and treatment-response variability. Int J Geriatr Psychiatry 2005;20:661-7
   PubMed Web of Science ®Google Scholar
• Pinquart M, Duberstein PR, Lyness JM. Treatments for later-life depressive conditions: a meta-analytic comparison of pharmacotherapy and psychotherapy Am J Psychiatry 2006;163:1493-501
   PubMed Web of Science ®Google Scholar
• Zis AP, Grof P, Webster M, Goodwin FK. Predictors of relapse in recurrent affective disorder. Psychopharmacol Bull 1980;16:47-9
   PubMedGoogle Scholar
• Kirsch I, Deacon BJ, Huedo-Medina TB, et al. Initial severity and antidepressant benefits: a meta-analysis of data submitted to the food and drug administration. PLoS Med 2008;5:e45
   PubMed Web of Science ®Google Scholar
• Turner EH, Matthews AM, Linardatos E, et al. Selective publication of antidepressant trials and its influence on apparent efficacy. NEJM 2008;358:252-60
   PubMed Web of Science ®Google Scholar
• Roose SP, Sackeim HA, Krishnan KR, et al. Antidepressant pharmacotherapy in the treatment of depression in the very old: a randomized, placebo-controlled trial. Am J Psychiatry 2004;161:2050-9
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Pollock BG. Aging and clinical pharmacology: implications for antidepressants. J Clin Pharmacol 2005;45:1106-22
   PubMed Web of Science ®Google Scholar
• Whyte EM, Dew MA, Gildengers AG, et al. Time course of response to antidepressants in late-life major depression: therapeutic implications. Drugs Aging 2004;21:531-54
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Pollock BG, Kirshner M, et al. Serotonine transporter genotype interacts with paroxetine plasma levels to influence depression treatment response in geriatric patients. J Psychiatry Neurosci 2008;33:123-30
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Pollock BG, Ferrell RE. Polymorphism of the serotonin transporter: implications for the use of selective serotonin reuptake inhibitors. Am J Pharmacogen 2001;1:153-64
   PubMedGoogle Scholar
• Lesch KP, Wolozin BL, Estler HC, et al. Isolation of a cDNA encoding the human brain serotonin transporter. J Neural Transm 1993;91:61-72
   Web of Science ®Google Scholar
• Hu XZ, Lipsky RH, Zhu G, et al. Serotonin transporter promoter gain-of-function genotypes are linked to obsessive-compulsive disorder. Am J Hum Genet 2006;78:815-26
   PubMed Web of Science ®Google Scholar
• Little KY, McLaughlin DP, Zhang L, et al. Cocaine, ethanol, and genotype effects on human midbrain serotonin transporter binding sites and mRNA levels. Am J Geriatr Psychiatry 1998;155:207-13
   Web of Science ®Google Scholar
• Heinz A, Jones DW, Mazzanti C, et al. A relationship between serotonin transporter genotype and in vivo protein expression and alcohol neurotoxicity. Biol Psychiatry 2000;47(47):643-9
   PubMed Web of Science ®Google Scholar
• Greenberg BD, Tolliver TJ, Huang SJ, et al. Genetic variation in the serotonin transporter promoter region affects serotonin uptake in human blood platelets. Am J Med Genet 1999;88:83-7
   PubMed Web of Science ®Google Scholar
• Heils A, Teufel A, Petri S, et al. Allelic variation of human serotonin transporter gene expression. J Neurochem 1996;66:2621-4
   PubMed Web of Science ®Google Scholar
• Rausch JL. Initial conditions of psychotropic drug response: Studies of serotonin transporter long promoter region (5-HTTLPR), serotonin transporter efficiency, cytokine and kinase gene expression relevant to depression and antidepressant outcome. Prog Neuropsychopharmacol Biol Psychiatry 2005;29:1046-61
   PubMed Web of Science ®Google Scholar
• Lesch KP, Bengel D, Heils A, et al. Association of anxiety-related traits with a polymorphism in the serotonin transporter gene regulatory region. Science 1996;274(5292):1527-31
   PubMed Web of Science ®Google Scholar
• Nakamura M, Ueno S, Sano A, Tanabe H. The human serotonin transporter gene linked polymorphism (5-HTTLPR) shows ten novel allelic variants. Mol Psychiatry 2000;5:32-8
   PubMed Web of Science ®Google Scholar
• Kilic F, Murphy DL, Rudnick G. A human serotonin transporter mutation causes constitutive activation of transport activity. Mol Psychiatry 2003;64:440-6
   Google Scholar
• Serretti A, Kato M, De Ronchi D, Kinoshita T. Meta-analysis of serotonin transporter gene promoter polymorphism (5-HTTLPR) association with selective serotonin reuptake inhibitor efficacy in depressed patients. Mol Psychiatry 2007;12:247-57
   PubMed Web of Science ®Google Scholar
• Caspi A, Sugden K, Moffitt TE, et al. Influence of life stress on depression: moderation by a polymorphism in the 5-HTT gene. Science 2003;301(5631):386-9
   PubMed Web of Science ®Google Scholar
• Hariri AR, Mattay VS, Tessitore A, et al. Serotonin transporter genetic variation and the response of the human amygdala. Science 2002;297(5580):400-3
   PubMed Web of Science ®Google Scholar
• Hong CJ, Chen TJ, Yu YW, Tsai SJ. Response to fluoxetine and serotonin 1A receptor (C-1019G) polymorphism in Taiwan Chinese major depressive disorder. Pharmacogenomics J 2006;6:27-33
   PubMed Web of Science ®Google Scholar
• Kunugi H, Hattori M, Kato T, et al. Serotonin transporter gene polymorphisms: ethnic difference and possible association with bipolar affective disorder. Mol Psychiatry 1997;2:457-62
   PubMed Web of Science ®Google Scholar
• Kim H, Lim SW, Kim S, et al. Monoamine transporter gene polymorphisms and antidepressant response in koreans with late-life depression. JAMA 2006;296:1609-18
   PubMed Web of Science ®Google Scholar
• Ozaki N, Goldman D, Kaye WH, et al. Serotonin transporter missense mutation associated with a complex neuropsychiatric phenotype. Mol Psychiatry 2003;8:933-6
   PubMed Web of Science ®Google Scholar
• Lovejoy EA, Scott AC, Fiskerstrand CE, et al. The serotonin transporter intronic VNTR enhancer correlated with a predisposition to affective disorders has distinct regulatory elements within the domain based on the primary DNA sequence of the repeat unit. Eur J Neurosci 2003;17:417-20
   PubMed Web of Science ®Google Scholar
• Mrazek DA, Rush AJ, Biernacka JM, et al. SLC6A4 variation and citalopram response. Am J Med Genet B Neuropsychiatr Genet 2008; published online 10 July 2008, doi:10.1002/ajmg.b.30816
   Google Scholar
• Sen S, Burmeister M, Ghosh D. Meta-analysis of the association between a serotonin transporter promoter polymorphism (5-HTTLPR) and anxiety-related personality traits. Am J Med Genet B Neuropsychiatr Genet 2004;127B1:85-9
   Google Scholar
• Lotrich FE, Pollock BG. Meta-analysis of serotonin transporter polymorphisms and affective disorders. Psychiatr Genet 2004;14:121-9
   PubMed Web of Science ®Google Scholar
• Hariri AR, Drabant EM, Munoz KE, et al. A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 2005;62:146-52
   PubMed Web of Science ®Google Scholar
• Heinz A, Braus DF, Smolka MN, et al. Amygdala-prefrontal coupling depends on a genetic variation of the serotonin transporter. Nat Neurosci 2005;8:20-1
   PubMed Web of Science ®Google Scholar
• Pezawas L, Meyer-Lindenberg A, Drabant EM, et al. 5-HTTLPR polymorphism impacts human cingulate-amygdala interactions: a genetic susceptibility mechanism for depression. Nat Neurosci 2005;8:828-34
   PubMed Web of Science ®Google Scholar
• Mayberg HS. Modulating dysfunctional limbic-cortical circuits in depression: towards development of brain-based algorithms for diagnosis and optimised treatment. Br Med Bull 2003;65:193-207
   PubMed Web of Science ®Google Scholar
• Ursu S, Stenger VA, Shear MK, et al. Overactive action monitoring in obsessive-compulsive disorder: evidence from functional magnetic resonance imaging. Psychol Sci 2003;14:347-53
   PubMed Web of Science ®Google Scholar
• Adler CM, Mc Donough-Ryan P, Sax KW, et al. fMRI of neuronal activation with symptom provocation in unmedicated patients with obsessive compulsive disorder. J Psychiatr Res 2000;34:317-24
   PubMed Web of Science ®Google Scholar
• Van Der Wee NJ, Ramsey NF, Jansma JM, et al. Spatial working memory deficits in obsessive compulsive disorder are associated with excessive engagement of the medial frontal cortex. Neuroimage 2003;20:2271-80
   PubMed Web of Science ®Google Scholar
• Rosenberg DR, Keshavan MS. Bennett Research Award: toward a neurodevelopmental model of obsessive–compulsive disorder. Biol Psychiatry 1998;43:623-40
   PubMed Web of Science ®Google Scholar
• Szeszko PR, Mac Millan S, Mc Meniman M, et al. Brain structural abnormalities in psychotropic drug-naive pediatric patients with obsessive-compulsive disorder. Am J Psychiatry 2004;161:1049-56
   PubMed Web of Science ®Google Scholar
• Frasure-Smith N, Lespérance F, Talajic M. Depression and 18-month prognosis after myocardial infarction. Circulation 1995;91:999-1005
   PubMed Web of Science ®Google Scholar
• Wellenius GA, Mukamal KJ, Kulshreshtha A, et al. Depressive symptoms and the risk of atherosclerotic progression among patients with coronary artery bypass grafts. Circulation 2008;117:2313-9
   PubMed Web of Science ®Google Scholar
• Pollock BG, Laghrissi-Thode F, Wagner WR. Evaluation of platelet activation in depressed patients with ischemic heart disease after paroxetine or nortriptyline treatment. J Clin Psychopharmacol 2000;20:137-40
   PubMed Web of Science ®Google Scholar
• Musselman DL, Tomer A, Manatunga AK, et al. Exaggerated platelet reactivity in major depression. Am J Psychiatry 1996;153:1313-7
   PubMed Web of Science ®Google Scholar
• Whyte EM, Pollock BG, Wagner WR, et al. Influence of serotonin-transporter-linked promoter region polymorphism on platelet activation in geriatric depression. Am J Psychiatry 2001;158:2074-6
   PubMed Web of Science ®Google Scholar
• Markovitz JH, Shuster JL, Chitwood WS, et al. Platelet activation in depression and effects of sertraline treatment: An open-label study. Am J Psychiatry 2000;157:1006-8
   PubMed Web of Science ®Google Scholar
• Musselman DL, Marzec UM, Manatunga A, et al. Platelet reactivity in depressed patients treated with paroxetine: preliminary findings. Arch Gen Psychiatry 2000;57:875-82
   PubMed Web of Science ®Google Scholar
• Taylor WD, Steffens DC, Payne ME, et al. Influence of serotonin transporter promoter region polymorphisms on hippocampal volumes in late-life depression. Arch Gen Psychiatry 2005;62:537-44
   PubMed Web of Science ®Google Scholar
• Brodaty H, Luscombe G, Parker G, et al. Early and late onset depression in old age: different aetiologies, same phenomenology. J Affect Disord 2001;66:225-36
   PubMed Web of Science ®Google Scholar
• Sapolsky RM. Glucocorticoids and hippocampal atrophy in neuropsychiatric disorders. Arch Gen Psychiatry 2000;57:925-35
   PubMed Web of Science ®Google Scholar
• Krishnan KR, Taylor WD, McQuoid DR, et al. Clinical characteristics of magnetic resonance imaging-defined subcortical ischemic depression. Biol Psychiatry 2004;55:390-7
   PubMed Web of Science ®Google Scholar
• Salloway S, Malloy P, Kohn R, et al. MRI and neuropsychological differences in early- and late-life-onset geriatric depression. Neurology 1996;46:1567-74
   PubMed Web of Science ®Google Scholar
• Du AT, Schuff N, Laakso MP, et al. Effects of subcortical ischemic vascular dementia and AD on entorhinal cortex and hippocampus. Neuroology 2002;58:1635-41
   PubMed Web of Science ®Google Scholar
• Alexopoulos GS, Young RC, Meyers BS. Geriatric depression: age of onset and dementia. Biol Psychiatry 1993;34:141-5
   PubMed Web of Science ®Google Scholar
• Steffens DC, Payne ME, Greenberg DL, et al. Hippocampal volume and incident dementia in geriatric depression. Am J Geriatr Psychiatry 2002;10:62-71
   PubMed Web of Science ®Google Scholar
• Murphy DL, Li Q, Engel S, et al. Genetic perspectives on the serotonin transporter. Brain Res Bull 2001;56:487-94
   PubMed Web of Science ®Google Scholar
• Bennett AJ, Lesch KP, Heils A, et al. Early experience and serotonin transporter gene variation interact to influence primate CNS function. Mol Psychiatry 2002;2002:118-22
   Google Scholar
• Lenze EJ, Munin MC, Ferrell RE, et al. Association of the serotonin transporter gene-linked polymorphic region (5-HTTLPR) genotype with depression in elderly persons after hip fracture. Am J Geriatr Psychiatry 2005;13:428-32
   PubMed Web of Science ®Google Scholar
• Ramasubbu R, Tobias R, Buchan AM, Bech-Hansen NT. Serotonin transporter gene promoter region polymorphism associated with poststroke major depression. J Neuropsychiatry Clin Neurosci 2006;18:96-9
   PubMed Web of Science ®Google Scholar
• Beard K. Adverse reactions as a cause of hospital admission in the aged. Drugs Aging 1992;2:356-67
   PubMed Web of Science ®Google Scholar
• Cooper JW. Probable adverse drug reactions in a rural geriatric nursing home population: a four-year study. J Am Geriatr Soc 1996;44:194-7
   PubMed Web of Science ®Google Scholar
• Gurwitz JH, Field TS, Avorn J, et al. Incidence and preventability of adverse drug events in nursing homes. Am J Med 2000;109:87-94
   PubMed Web of Science ®Google Scholar
• Mottram P, Wilson K, Strobl J. Antidepressants for depressed elderly. Cochrane Database Syst Rev 2006;25:CD003491
   Google Scholar
• Van Walraven C, Mamdani MM, Wells PS, Williams JI. Inhibition of serotonin reuptake by antidepressants and upper gastrointestinal bleeding in elderly patients: retrospective cohort study. BMJ 2001;323:655-8
   PubMed Web of Science ®Google Scholar
• Gibbons RD, Brown CH, Hur K, et al. Relationship between antidepressants and suicide attempts: an analysis of the veterans health administration data sets. Am J Psychiatry 2007;164:1044-9
   PubMed Web of Science ®Google Scholar
• Bigos KL, Pollock BG, Aizenstein HJ, et al. Acute 5-HT Reuptake Blockade Potentiates Human Amygdala Reactivity. Neuropsychopharmacology 2008; published online 7 May 2008, doi:10.1038/npp.2008.52
   PubMedGoogle Scholar
• Harmer CJ, Mackay CE, Reid CB, et al. Antidepressant drug treatment modifies the neural processing of nonconscious threat cues. Biol Psychiatry 2006;59:816-20
   PubMed Web of Science ®Google Scholar
• Murphy GMJ, Hollander SB, Rodrigues HE, et al. Effects of the serotonin transporter gene promoter polymorphism on mirtazapine and paroxetine efficacy and adverse events in geriatric major depression. Arch Gen Psychiatry 2004;61:1163-9
   PubMed Web of Science ®Google Scholar
• Perlis RH, Mischoulon D, Smoller JW, et al. Serotonin transporter polymorphisms and adverse effects with fluoxetine treatment. Biol Psychiatry 2003;54:879-83
   PubMed Web of Science ®Google Scholar
• Chen JJ, Li Z, Pan H, et al. Maintenance of serotonin in the intestinal mucosa and ganglia of mice that lack the high-affinity serotonin transporter: Abnormal intestinal motility and the expression of cation transporters. J Neurosci 2001;21:6348-61
   PubMed Web of Science ®Google Scholar
• Kim DY, Camilleri M. Serotonin: a mediator of the brain-gut connection. Am J Gastroenterol 2000;95:2698-709
   PubMed Web of Science ®Google Scholar
• Hu XZ, Rush AJ, Charney D, et al. Association between a functional serotonin transporter promoter polymorphism and citalopram treatment in adult outpatients with major depression. Arch Gen Psychiatry 2007;64:783-92
   PubMed Web of Science ®Google Scholar
• Rausch JL, Johnson ME, Fei YJ, et al. Initial conditions of serotonin transporter kinetics and genotype: influence on SSRI treatment trial outcome. Biol Psychiatry 2002;51:723-32
   PubMed Web of Science ®Google Scholar
• Sindrup SH, Grodum E, Gram LF, Beck-Nielsen H. Concentration-response relationship in paroxetine treatment of diabetic neuropathy symptoms: a patient-blinded dose-escalation study. Drug Monit 1991;13:408-14
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Recent dose-effect studies regarding antidepressants. In: Balant LP, editor, Clinical pharmacology in psychiatry: finding the right dose of psychotropic drugs conference, October 23-25, 1997, 1998; Badajoz, Spain: Luxembourg: European Commission, Directorate-General Science, Research and Development; 1998. p. 43-62
   Google Scholar
• Bollini P, Pampallona S, Tibaldi G, et al. Effectiveness of antidepressants. Meta-analysis of dose-effect relationships in randomised clinical trials. Br J Psychiatry 1999;174:297-303
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Bies R, Muldoon MF, et al. Neuroendocrine response to intravenous citalopram in healthy control subjects: pharmacokinetic influences. Psychopharmacology 2005;178:268-75
   PubMed Web of Science ®Google Scholar
• Henry ME, Moore CM, Kaufman MJ, et al. Brain kinetics of paroxetine and fluoxetine on the third day of placebo substitution: a fluorine MRS study. Am J Psychiatry 2000;157:1506-8
   PubMed Web of Science ®Google Scholar
• Papakostas GI, Petersen T, Iosifescu DV, et al. Obesity among outpatients with major depressive disorder. Int J Neuropsychopharmacol 2005;8:59-63
   PubMed Web of Science ®Google Scholar
• Hirano K, Kimura R, Sugimoto Y, et al. Relationship between brain serotonin transporter binding, plasma concentration and behavioural effect of selective serotonin reuptake inhibitors. Br J Pharmacol 2005;144:695-702
   PubMed Web of Science ®Google Scholar
• Baker CB, Tweedie R, Duval S, Woods SW. Evidence that the SSRI dose response in treating major depression should be reassessed: a meta-analysis. Depress Anxiety 2003;17:1-9
   PubMed Web of Science ®Google Scholar
• Tasker TC, Kaye CM, Zussman BD, Link CG. Paroxetine plasma levels: lack of correlation with efficacy or adverse events. Acta Psychiatr Scand Suppl 1989;350:152-5
   PubMedGoogle Scholar
• Amsterdam JD, Fawcett J, Quitkin FM, et al. Fluoxetine and norfluoxetine plasma concentrations in major depression: a multicenter study. Am J Psychiatry 1997;154:963-9
   PubMed Web of Science ®Google Scholar
• Normann C, Hörn M, Hummel B, et al. Paroxetine in major depression: correlating plasma concentrations and clinical response. Pharmacopsychiatry 2004;37:123-6
   PubMed Web of Science ®Google Scholar
• Reis M, Aberg-Wistedt A, Agren H, et al. Serum disposition of sertraline, N-desmethylsertraline and paroxetine: a pharmacokinetic evaluation of repeated drug concentration measurements during 6 months of treatment for major depression. Hum Psychopharmacol 2004;19:283-91
   PubMed Web of Science ®Google Scholar
• Solai LK, Pollock BG, Mulsant BH, et al. Effect of nortriptyline and paroxetine on CYP2D6 activity in depressed elderly patients. J Clin Psychopharmacol 2002;22:481-6
   PubMed Web of Science ®Google Scholar
• Meyer JH, Wilson AA, Sagrati S, et al. Serotonin transporter occupancy of five selective serotonin reuptake inhibitors at different doses: an [11C]DASB positron emission tomography study. Am J Psychiatry 2004;161:826-35
   PubMed Web of Science ®Google Scholar
• Frazer A. Serotonergic and noradrenergic reuptake inhibitors: prediction of clinical effects from in vitro potencies. J Clin Psychiatry 2001;62(Suppl 12):16-23
   PubMedGoogle Scholar
• Smith GS, Lotrich FE, Malhotra AK, et al. Effects of serotonin transporter promoter polymorphisms on serotonin function. Neuropsychopharmacology 2004;29:2226-34
   PubMed Web of Science ®Google Scholar
• Parsey RV, Hastings RS, Oquendo MA, et al. Effect of a triallelic functional polymorphism of the serotonin-transporter-linked promoter region on expression of serotonin transporter in the human brain. Am J Psychiatry 2006;163:48-51
   PubMed Web of Science ®Google Scholar
• Kraft JB, Peters EJ, Slager SL, et al. Analysis of association between the serotonin transporter and antidepressant response in a large clinical sample. Biol Psychiatry 2007;61:734-42
   PubMed Web of Science ®Google Scholar
• McMahon FJ, Buervenich S, Charney D, et al. Variation in the gene encoding the serotonin 2A receptor is associated with outcome of antidepressant treatment. Am J Hum Genet 2006;78:804-14
   PubMed Web of Science ®Google Scholar
• Pollock BG, Ferrell RE, Mulsant BH, et al. Allelic variation in the serotonin transporter promoter affects onset of paroxetine treatment response in late-life depression. Neuropsychopharmacology 2000;23:587-90
   PubMed Web of Science ®Google Scholar
• Durham LK, Webb SM, Milos PM, et al. The serotonin transporter polymorphism, 5-HTTLPR, is associated with a faster response time to sertraline in an elderly population with major depressive disorder. Psychopharmacol 2004;174:525-9
   PubMed Web of Science ®Google Scholar
• Zanardi R, Benedetti F, Di Bella D, et al. Efficacy of paroxetine in depression is influenced by a functional polymorphism within the promoter of the serotonin transporter gene. J Clin Psychopharmacol 2000;20:105-7
   PubMed Web of Science ®Google Scholar
• Yoshida K, Ito K, Sato K, et al. Influence of the serotonin transporter gene-linked polymorphic region on the antidepressant response to fluvoxamine in Japanese depressed patients. Prog Neuropsychopharmacol Biol Psychiatry 2002;26:383-6
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Bies RR, Smith GS, Pollock BG. Relevance of assessing drug concentration exposure in pharmacogenetic and imaging studies. J Psychopharmacol 2006;20:33-40
   PubMed Web of Science ®Google Scholar
• Simon GE, Von Korff M, Wagner EH, Barlow W. Patterns of antidepressant use in community practice. Gen Hosp Psychiatry 1993;15:399-408
   PubMed Web of Science ®Google Scholar
• Preskorn SH. Recent dose-effect studies regarding antidepressants. In: Balant LP, editor, Clinical pharmacology in psychiatry: finding the right dose of psychotropic drugs conference, October 23-25, 1997; Badajoz, Spain: Luxembourg: European Commission, Directorate-General Science, Research and Development; 1997. p. 43-62
   Google Scholar
• Szegedi A, Müller MJ, Anghelescu I, et al. Early improvement under mirtazapine and paroxetine predicts later stable response and remission with high sensitivity in patients with major depression. J Clin Psychiatry 2003;64:413-20
   PubMed Web of Science ®Google Scholar
• Lotrich FE, Pollock BG. Candidate genes for antidepressant response to selective serotonin reuptake inhibitors. Neuropsychiatr Dis Treat 2005;1:17-35
   PubMedGoogle Scholar